Rep. Kevin Hern (R-OK) Sells Boston Scientific (BSX) Stock
Oklahoma Congressman Kevin Hern sold shares of Boston Scientific valued between $50,001 and $100,000.
Reviewed by automated data checks against the source filing. How we make and check alerts
Rep. Kevin Hern (R-OK) sold between $50,001 and $100,000 of Boston Scientific Corporation ($BSX) stock on September 9, 2026. The trade was disclosed in a STOCK Act periodic transaction report filed September 25, 2026.
Since the trade, $BSX is down 2.3% after 1 week, down 5.0% after 1 month and down 1.3% to date (from the $44.96 close on Sep 9, 2026).
Financial Disclosure Report
Clerk of the House of Representatives • Legislative Resource Center • B81 Cannon Building • Washington, DC 20515
Filer Information
- Name:
- Rep. Kevin Hern (R-OK)
- Status:
- Member — House
- State/District:
- OK-1
- Party:
- Republican
Filing Information
- Filing Type:
- Periodic Transaction Report
- Filing Year:
- 2026
- Filing Date:
- Sep 25, 2026
Schedule B: Transactions
| Asset | Transaction | Date | Amount |
|---|---|---|---|
| Boston Scientific Corporation ($BSX) | Sell | Sep 9, 2026 | $50,001 - $100,000 |
Summary of the filed report, not the original document. Find the original: House financial disclosure search
BSX
Boston Scientific Corporation
Key Points
- Kevin Hern sold shares of Boston Scientific Corporation (BSX) valued between $50,001 and $100,000 on September 9, 2026.
- The stock was trading at $44.12 on the date of the sale, slightly above its previous close of $43.00.
- Boston Scientific has a market cap of about $63.97 billion and a P/E ratio of 17.87.
Get $BSX trade alerts by text
We text you when insiders, Congress or big funds trade $BSX. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Boston Scientific Corporation alert may contain errors. Disclosures
Oklahoma Congressman Kevin Hern sold shares of Boston Scientific Corporation (BSX) on September 9, 2026. The transaction was valued between $50,001 and $100,000. Hern reported this trade on September 25, 2026.
Kevin Hern vs. the S&P 500
Hypothetical returns from Kevin Hern's disclosed trades, not real profit or advice. How we model this.
Inside Kevin Hern's Trade
Hern's sale occurred when Boston Scientific shares were priced at $44.12. This price was higher than its previous close of $43.00, indicating a slight upward trend in the stock preceding his sale. The company operates in the healthcare sector, specifically creating medical devices used worldwide across various medical specialties.
Other Institutional Activity in Boston Scientific
Several institutional investors adjusted their positions in Boston Scientific recently. Blackrock Inc. trimmed its stake by 2,135,425 shares, ending with 129,680,916 shares valued at about $5.72 billion. Vanguard Capital Management LLC increased its holdings, adding 674,889 shares for a total of 97,087,553 shares worth around $4.28 billion. State Street Corporation also grew its position by 2,121,285 shares, bringing its total to 70,111,196 shares valued at $3.09 billion. In contrast, FMR, LLC cut its stake significantly, selling 28,526,236 shares and ending with 45,702,845 shares valued at roughly $2.02 billion.
Boston Scientific Corporation Stock Up 2.6%
As of today, Boston Scientific shares trade at approximately $44.12, just above its 52-week low of $41.39 but far from its 52-week high of $105.65. The stock is currently below its 50-day moving average of $46.18, which may indicate some weakness in the short term.
Recent Earnings
In its latest earnings report, Boston Scientific generated revenue of $20.99 billion, reflecting a year-over-year growth of 7.5%. The company posted an EPS of $2.47, with a net margin of 17.5%. Its next earnings report is scheduled for October 28, 2026.
Earnings drift grade
Outlook vs expectations on the last report — not price action.
-
Forward outlook
12 target cuts vs 1 raises.
-
EPS & revenue
EPS beat estimates by 0.7%. Revenue met estimates.
-
Profit surprise
EBITDA met by 0 percent. Operating income missed by 13 percent.
-
Pre-earnings setup
Bar was high, analysts already very bullish.
-
Analyst signal
1 target raise, 12 target cuts.
-
Earnings quality
Gross margin up 6.2 points. Operating margin up 1.4 points. Positive free cash flow.
Earnings Call Summary
Boston Scientific reported first quarter sales of $5.2 billion, up 9.4 percent, and beat on earnings at $0.80 per share. However, management revealed major headwinds in three key franchises. The EP cardiology ablation business, which grew 22 percent this quarter, is now expected to slow to 10 percent full year as competition from Medtronic, J and J, and Abbott pressures U.S. share. WATCHMAN, which grew 19 percent, slowed sharply in February as stand-alone procedures fell even as concomitant adoption grew. Urology nearly flatlined at 1 percent growth due to problems in stone management and sacral neuromodulation. Management said the company lost more market share than expected and hospital capacity constraints are limiting WATCHMAN procedure volume.
Guidance The company cut its full year sales growth guidance from an expected 8 to 10 percent range down to 6.5 to 8 percent. They expect second quarter sales to grow only 5 to 7 percent year over year. The company now guides full year earnings per share to $3.34 to $3.41, still up 9 to 11 percent but well below prior expectations.
Severe negative reset. The report materially damaged the forward outlook and likely forces major downward revisions.
Insider Buying and Selling at Boston Scientific Corporation
There have been notable insider trades at Boston Scientific recently. Director Susan E. Morano purchased 2,040 shares on August 25, 2026, for about $100,408. Another Director, David C. Habiger, acquired 2,100 shares on August 5, 2026, valued at approximately $99,937, followed by a purchase of 1,182 shares on August 4, 2026, amounting to around $56,887. CEO Michael F. Mahoney bought 186,240 shares on August 3, 2026, for a total of about $9.00 million.
Analysts Set New Price Targets
On October 14, 2026, Truist Securities maintained its "Buy" rating on the stock with a price target of $51.00, down from a prior target of $57.00. Barclays initiated coverage with an "Equal-Weight" rating and a target of $48.00 on October 7, 2026. Citigroup also maintained a "Neutral" rating with a target of $48.00 on October 5, 2026. Wells Fargo kept its "Equal-Weight" rating with a target of $48.00 on September 24, 2026. The consensus among analysts suggests a "Buy" recommendation with an average target price of $59.24 from 29 opinions.
About Boston Scientific Corporation
Boston Scientific Corporation, headquartered in Marlborough, Massachusetts, designs and manufactures medical devices for various interventional medical specialties. With a workforce of around 59,000 employees, the company plays a significant role in improving patient health outcomes globally. The recent share sale by Congressman Hern occurs in the context of a company that is pivotal in the healthcare sector.
Bottom Line
Investors will be watching Boston Scientific closely, especially with its next earnings report coming up on October 28, 2026. The filing details of Hern's transaction are public records and show the congressman’s stock activities. This 13F filing reflects a past position that may not indicate current holdings.
Related Filing Alerts
Source: Kevin Hern's STOCK Act disclosure on $BSX (Sep 9, 2026). Find the original filing: House financial disclosure search. Written by software, not financial advice. How we make alerts